Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Nuvation Bio Q3 2025 Earnings Call - ATROSY Achieves Record-Setting U.S. Launch and Expands Commercial Momentum
Nuvation Bio marked its first full quarter as a commercial-stage company with a robust launch of its lead product, ATROSY, for ROS1-positive non-small cell lung cancer (NSCLC). Q3 saw 204 new patient ...
- ATROSY launched commercially in the U.S. in Q3 2025 with 204 new patient starts, averaging over 15 per week, far exceeding the launch speed of the closest competitor, Oqtyro.
- Median duration of response (DOR) for ATROSY in TKI-naive patients extended to 50 months, indicating unprecedented durability in ROS1-positive NSCLC.
- Patient coverage expanded rapidly to over 80% of U.S. lives within months of launch, reflecting swift payer adoption and effective market access efforts.
- +12 more takeaways
Syndax Pharmaceuticals Q3 2025 Earnings Call - Accelerated Growth and Expanding Leadership in Menin Inhibition with Revyforge and Nictimvo
Syndax Pharmaceuticals reported robust Q3 2025 results fueled by significant commercial traction of its two flagship drugs, Revyforge and Nictimvo. Revyforge's net revenue surged 12% to $32 million de...
- Syndax posted $45.9 million total revenue in Q3 2025, a 21% increase over the prior quarter, driven by strong commercial demand.
- Revyforge net revenue grew 12% quarter-over-quarter to $32 million, despite a one-third patient treatment pause for stem cell transplants.
- Revyforge prescriptions and new patient starts increased ~25% in Q3, showing growing adoption and demand.
- +13 more takeaways
Harmonic Q3 2025 Earnings Call - DOCSIS 4.0 and Fiber Drive Robust Growth with Expanding SaaS Momentum
Harmonic delivered a strong third quarter for 2025 with total revenue of $142.4 million, surpassing guidance. The broadband segment led with $90.5 million in revenue, powered by unified Remote PHY Dev...
- Q3 2025 revenue reached $142.4 million, exceeding company guidance.
- Broadband segment revenue was $90.5 million with 47.3% gross margin, driven by unified RPD and fiber deployments.
- Harmonic completed the industry's first live extended spectrum deployment of unified DOCSIS 4.0 with Mediacom.
- +13 more takeaways
Upwork Q3 2025 Earnings Call - AI-Driven Growth Reignites GSV Expansion and Profitability
Upwork's Q3 2025 marks a pivotal turn as the company breaks through a multi-quarter GSV growth stall, delivering 2% year-over-year expansion and record revenue surpassing $200 million. This rebound re...
- Upwork achieved 2% year-over-year growth in Gross Services Volume (GSV) in Q3 2025, ending a five-quarter decline trend.
- Quarterly revenue surpassed $200 million for the first time, reaching $201.7 million, with GAAP net income at $29.3 million.
- Adjusted EBITDA hit a record $59.6 million with a 29.6% margin, marking a more than six-point margin expansion year-over-year.
- +12 more takeaways
Adeia 3Q 2025 Earnings Call - Litigation With AMD Delays Revenue, But Growth Pipeline Remains Robust
Adeia reported third quarter 2025 revenue of $87.3 million, aligning with expectations, yet revised full-year guidance down to $360-$380 million due to the unlikely closure of a previously anticipated...
- Q3 2025 revenue was $87.3 million, meeting company expectations.
- Non-Pay TV recurring revenue grew 31% year-over-year in Q3, evidencing successful diversification.
- Adeia filed multiple patent infringement lawsuits against AMD, halting expected licensing agreement and causing revenue guidance reduction.
- +12 more takeaways
Superior Group of Companies Q3 2025 Earnings Call - Navigating Uncertainty with Strategic Cost Cuts and Growing Pipelines
Superior Group of Companies reported a 7% year-over-year revenue decline in Q3 2025, reflecting ongoing market uncertainties and prior quarter sales pull-forward. However, the company offset revenue h...
- Superior Group’s Q3 2025 revenues declined 7% year-over-year to $138 million, pressured by prior quarter sales pull-forward and a strong Q3 last year.
- SG&A expenses were cut by 7%, saving approximately $4 million year-over-year, reflecting a sharp focus on cost discipline starting mid-2025.
- Branded products segment revenue fell 8% to $85 million due to sales timing, lower employee turnover at client companies, smaller order sizes, and delayed ordering.
- +17 more takeaways
Sarepta Therapeutics Q3 2025 Earnings Call - Strong PMO Data Supports Path to Traditional Approval Despite ESSENCE Trial Challenges
Sarepta Therapeutics reported solid Q3 2025 results, driven by $370 million net product revenue, including $131 million from Elevidys and $239 million from exon-skipping PMOs treating Duchenne muscula...
- Sarepta completed confirmatory ESSENCE trial of exon-skipping therapies Vyondys 53 and Amondys 45 in Duchenne muscular dystrophy with 225 patients across 24 countries.
- ESSENCE showed numerical superiority but missed primary endpoint statistical significance at 96 weeks due to COVID-19 pandemic impacts and patient dose misses.
- Excluding COVID-impacted patients, ESSENCE showed a ~30% slowing of disease progression with a p-value of 0.09, nearing conventional statistical significance.
- +12 more takeaways
Kforce Q3 2025 Earnings Call - Solid Q3 Beats Amid AI-Driven Transition and Strategic Growth
Kforce delivered a strong third quarter, beating revenue and EPS expectations with $332.6 million in revenue and $0.63 earnings per share. The technology business showed resilience despite a slight se...
- Kforce Q3 revenues of $332.6 million and EPS of $0.63 exceeded high-end guidance.
- Technology segment revenues declined slightly sequentially and year-over-year but showed a 4% increase in consultants on assignment from early Q3 lows.
- Finance & Accounting (FA) business grew 7% sequentially, marking consecutive quarters of growth, though still down year-over-year.
- +17 more takeaways
PLAYSTUDIOS Q3 2025 Earnings Call - Navigating Structural Headwinds with Sweepstakes and Tetris Growth Initiatives
PLAYSTUDIOS reported a tough quarter marked by ongoing declines in core social casino revenue and player activity amid challenging market headwinds. Revenue fell 19.1% year-over-year to $57.6 million,...
- Total Q3 2025 revenue declined 19.1% year-over-year to $57.6 million, and adjusted EBITDA dropped 50.5% to $7.2 million, signaling significant pressure on financial results.
- Monthly active users (MAU) and daily active users (DAU) fell about 25% compared to last year, mainly in the casual gaming segment, consistent with broader industry contraction.
- CEO Andrew Pascal acknowledged a challenging operating environment and stressed urgency in repositioning the business with an aligned board and leadership team, emphasizing no strategy is off the table.
- +12 more takeaways
TrueBlue Q3 2025 Earnings Call - Strategic Growth in Skilled Staffing and Digital Innovation Drive Revenue Up 13%
TrueBlue exceeded expectations in Q3 2025, posting 13% revenue growth to $431 million driven by strong performance in skilled staffing sectors including more than doubled energy sector revenue and a f...
- TrueBlue's Q3 2025 revenue rose 13%, beating guidance, to $431 million aided by skilled staffing growth.
- Energy sector revenue more than doubled, reflecting strong market position and expanding demand.
- Commercial driver business achieved fifth straight quarter of double-digit revenue growth, taking market share.
- +9 more takeaways